India's BioPharma SHAKTI Boosts Non-Animal Drug Development
India's BioPharma SHAKTI strategy aims to revolutionize biologics production using advanced non-animal models.
Photo by Microsoft Copilot
Quick Revision
Biologics are large, complex molecules produced by living cells, including monoclonal antibodies, vaccines, and insulin.
Animal models may not reliably predict the safety and efficacy of biologics due to species differences.
The Northwick Park Tragedy in 2006 involved six healthy men developing multiple organ failure during a clinical trial of theralizumab, which was not observed in preclinical animal tests.
In 2022, the monoclonal antibody semorinemab failed in phase II trials for Alzheimer's disease despite showing effectiveness in preclinical mouse models.
Non-Animal Methodologies (NAMs) include organoids, organ-on-a-chip, and 3D bioprinting, which are derived from human cells.
NAMs replicate human biology more faithfully than animal models, offering more reliable drug testing.
A 2019 analysis estimated that organ-on-chip technologies could lower overall drug development costs by 10-26% and reduce lead optimisation time by 19%.
The New Drugs and Clinical Trials (Amendment) Rules 2023 in India promote the use of NAMs in novel drug development.
Biosimilars are generic versions of biologics, reverse-engineered once the original product's patent expires.
The Central Drugs Standard Control Organisation (CDSCO) is India's apex regulatory body for approving biosimilars.
Key Dates
Key Numbers
Visual Insights
India's BioPharma SHAKTI Strategy: Key Highlights
Key statistics and focus areas of the BioPharma SHAKTI strategy announced in the 2026 Union Budget.
- Strategy Focus
- Enhancing domestic production of biologics and biosimilars
- Promoted Methodologies
- Non-Animal Methodologies (NAMs)
- Key Benefit of NAMs
- More reliable drug testing than traditional animal models
Aims to boost India's self-reliance in critical pharmaceutical sectors.
Emphasis on advanced techniques like organoids and 3D bioprinting for more reliable drug testing.
Addresses past clinical trial failures attributed to limitations of animal testing.
Mains & Interview Focus
Don't miss it!
The BioPharma SHAKTI strategy, unveiled in the 2026 Union Budget, represents a critical policy pivot towards bolstering India's biopharmaceutical sector. This initiative correctly identifies the growing global significance of biologics and biosimilars, a class of drugs increasingly vital for chronic disease management. By allocating a substantial ₹10,000 crore, the government signals a serious commitment to domestic production and technological advancement in this high-value domain.
A key strength of this strategy lies in its explicit promotion of Non-Animal Methodologies (NAMs). Past incidents, such as the Northwick Park Tragedy in 2006 involving theralizumab, starkly demonstrated the inherent unreliability of animal models for predicting human drug responses. NAMs, including organoids and 3D bioprinting, offer a scientifically superior and ethically sound alternative, promising not only more accurate safety and efficacy data but also potential reductions in drug development costs and timelines.
However, the successful implementation of BioPharma SHAKTI hinges on overcoming significant systemic hurdles. Despite the New Drugs and Clinical Trials (Amendment) Rules 2023 promoting NAMs, their commercialization remains nascent due to issues of accessibility, sustained funding, and a lack of robust entrepreneurial ecosystem. Merely providing funds is insufficient; a concerted effort is required to build infrastructure, foster skilled human capital, and streamline technology transfer from academia to industry.
Furthermore, regulatory clarity from bodies like the Central Drugs Standard Control Organisation (CDSCO) is paramount. The current draft guidelines for biosimilars, particularly concerning NAMs, require accelerated finalization and clear implementation pathways. Addressing challenges like patent evergreening, which delays the availability of affordable biosimilars, demands proactive government intervention to ensure the policy's intended benefits reach the wider population. India must learn from the U.K.'s roadmap to phase out animal experiments and expedite its own regulatory evolution.
Exam Angles
GS Paper III: Science and Technology - advancements in drug development, biotechnology, ethical considerations in research.
GS Paper III: Economy - impact on pharmaceutical industry, cost reduction, innovation, market competitiveness.
GS Paper II: Governance - regulatory frameworks, policy initiatives, public-private partnerships.
Ethical considerations in scientific research and development.
View Detailed Summary
Summary
India's new BioPharma SHAKTI plan aims to boost the domestic production of advanced medicines called biologics and their generic versions. It promotes using human cell models instead of animals for drug testing, making drug development safer, faster, and more reliable for patients.
The 2026 Union Budget has launched the BioPharma SHAKTI strategy to significantly boost domestic production of biologics and biosimilars. This ambitious initiative strongly promotes the adoption of Non-Animal Methodologies (NAMs) for drug development and testing. NAMs include advanced techniques like organoids and 3D bioprinting, which are increasingly seen as more reliable and predictive than traditional animal testing models. Past failures in clinical trials, often attributed to the limitations of animal models, underscore the need for these newer methods. BioPharma SHAKTI aims to leverage NAMs to reduce drug development costs and accelerate timelines. However, the widespread commercialization of NAMs in India faces hurdles. These include ensuring accessibility of the technology, securing adequate funding for research and development, and establishing clear regulatory pathways, particularly for biosimilars. The strategy's success hinges on overcoming these challenges to make India a global hub for innovative and ethical drug development.
This development is crucial for India's pharmaceutical sector, aligning with global trends towards more humane and scientifically advanced drug testing. It has direct relevance to UPSC examinations, particularly in Science & Technology and Economy papers.
Background
Latest Developments
The 2026 Union Budget's introduction of the BioPharma SHAKTI strategy marks a significant policy intervention aimed at bolstering India's position in the global biopharmaceutical market. The strategy explicitly encourages the integration of NAMs into the drug development pipeline.
Challenges in adopting NAMs include the need for substantial investment in infrastructure and training, as well as the development of standardized protocols and validation frameworks. Regulatory clarity is paramount, especially for biosimilars, where demonstrating equivalence to existing biologics can be complex. The government's role is crucial in providing financial incentives, fostering public-private partnerships, and streamlining regulatory approvals for NAM-based research and products.
The long-term vision is to reduce India's reliance on animal testing, enhance the predictive accuracy of drug testing, and potentially lower the cost of medicines. This aligns with global ethical standards and scientific advancements, positioning India as a leader in responsible pharmaceutical innovation.
Practice Questions (MCQs)
1. Consider the following statements regarding Non-Animal Methodologies (NAMs) in drug development: 1. NAMs include techniques like organoids and 3D bioprinting. 2. NAMs are primarily aimed at replacing traditional animal testing due to ethical concerns and predictive limitations. 3. The BioPharma SHAKTI strategy explicitly promotes the adoption of NAMs in India. Which of the statements given above is/are correct?
- A.1 only
- B.1 and 2 only
- C.2 and 3 only
- D.1, 2 and 3
Show Answer
Answer: D
Statement 1 is CORRECT. NAMs encompass advanced techniques such as organoids (miniature organs grown in vitro) and 3D bioprinting, which mimic human tissues and organs. Statement 2 is CORRECT. NAMs are promoted to overcome the ethical issues associated with animal testing and to provide more accurate predictions of drug responses in humans, as animal models do not always translate well to human physiology. Statement 3 is CORRECT. The BioPharma SHAKTI strategy, launched in the 2026 Union Budget, specifically aims to enhance domestic production by promoting NAMs.
2. Which of the following are key challenges faced in the commercialization of Non-Animal Methodologies (NAMs) in India, as highlighted by the BioPharma SHAKTI strategy?
- A.Lack of scientific interest and skilled personnel
- B.High cost of animal testing and limited availability of lab animals
- C.Regulatory clarity, funding accessibility, and technology accessibility
- D.Over-reliance on international collaborations for technology transfer
Show Answer
Answer: C
The summary explicitly mentions that commercialization faces challenges in 'accessibility, funding, and regulatory clarity'. Option A is incorrect as the strategy implies scientific interest and aims to build capacity. Option B describes potential limitations of animal testing, not challenges for NAMs. Option D might be a factor in some cases but is not the primary challenge listed in the source.
3. Which of the following statements best describes the advantage of Non-Animal Methodologies (NAMs) over traditional animal testing in drug development?
- A.NAMs are mandated by all international pharmaceutical regulatory bodies.
- B.NAMs offer more reliable predictions of drug effects in humans and can reduce development costs.
- C.Animal testing is being completely phased out globally due to NAM advancements.
- D.NAMs are exclusively used for testing cosmetic products, not therapeutic drugs.
Show Answer
Answer: B
Statement B accurately reflects the advantages mentioned: NAMs are considered more reliable for predicting human responses, and by reducing the need for extensive animal trials and potentially shortening development timelines, they can lower costs. Statement A is incorrect as regulatory acceptance is evolving, not universal. Statement C is incorrect; animal testing is still widely used, though NAMs are gaining traction. Statement D is incorrect; NAMs are applied to therapeutic drug development.
4. Consider the following statements: 1. Biologics are complex molecules derived from living organisms, used to treat diseases like cancer and autoimmune disorders. 2. Biosimilars are highly similar to an already approved biologic drug (the reference product) and have no clinically meaningful differences in safety and efficacy. 3. The development and approval process for biosimilars is identical to that of generic small-molecule drugs. Which of the statements given above is/are correct?
- A.1 only
- B.1 and 2 only
- C.2 and 3 only
- D.1, 2 and 3
Show Answer
Answer: B
Statement 1 is CORRECT. Biologics are indeed complex protein-based drugs derived from living cells or organisms. Statement 2 is CORRECT. Biosimilars are designed to be highly similar to reference biologics, with no significant differences in terms of safety, purity, and potency. Statement 3 is INCORRECT. Biosimilars are much more complex to develop and approve than generic small-molecule drugs due to the inherent complexity of biologics. Their approval requires extensive analytical, clinical, and pharmacokinetic studies to demonstrate similarity.
Source Articles
How BioPharma SHAKTI can transform biologics with non-animal models - The Hindu
More, and less: On Budget 2026 and health-care spending - The Hindu
NIPER Raebareli partners with Roche Pharma to Strengthen Pharmaceutical Education and Research Capability Building Collaboration - The Hindu
Biotechnology is set to drive the evolution of personalised medicine, say experts - The Hindu
About the Author
Ritu SinghTech & Innovation Current Affairs Researcher
Ritu Singh writes about Science & Technology at GKSolver, breaking down complex developments into clear, exam-relevant analysis.
View all articles →